Redirecting to Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021 q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Accelerated Cost Synergies and Achieved $2.3 Billion Target One Year Ahead of Plan
Reported Net Profit Growth of Approximately +750% YOY, Reflecting Gains on Non-core Asset Sales and Lower Acquisition-related Expenses
Robust Operating Cash Flow and Divestiture Proceeds Resulting in Free Cash Flow of JPY 1,237.8 Billion, Driving Deleveraging to Net Debt / Adjusted EBITDA of 3.2x
FY2021 Anticipated to be an Inflection Year for Wave 1 Pipeline with Five to Six Wave 1 NMEs Submitted and Under Regulatory Review by the FDA with the Potential for Four Approvals
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021).
Sponsored
Constant evolution in the face of challenges is what unites the top-scoring chief executives in
Institutional Investor’s 2021 All-Japan Executive Team. Shigenobu Nagamori, chairman and chief executive of Nidec Corp., quotes Nietzsche: “The snake which cannot cast its skin has to die.”
Nagamori is once again the top-scoring chief executive in the electronic components sector for his work at Nidec, the company he founded in a prefabricated hut along the Katsura River in Kyoto in 1973. For more than 10 years, he has been searching for a successor for his business. But few hopefuls can match his resolve: After his father passed away when he was a child, Nagamori’s mother, a farmer, told him that as long as he put in twice as much effort as others, he would succeed in his endeavors.
COVID-19 survivors can help others in a different way: donating their plasma
Medical professional holds bags of blood donations (Photo credit: Ahmad Ardity- Pixabay)
The Fight Is In Us campaign is calling upon all COVID-19 survivors across the nation, including Arizonans to donate their plasma to help those who are suffering from the virus.
Its message is to provide those survivors with the vital antibodies in their blood plasma that could be used to help others fight off the disease, or better yet, to create a medicine to potentially treat it.
In a press release, the campaign describes itself as a coalition made up of various medical and research institutions, blood centers among other companies and organizations coming together to support the rapid development of potential new therapies for patients with the coronavirus.
CoVIg-19 Plasma Alliance announces outcomes of NIH-funded Phase 3 ITAC clinical trial
Apr 7 2021
The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised in the trial.
The study aimed to determine whether an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine (referred to by the Alliance as CoVIg-19) could reduce the risk of disease progression when added to standard of care treatment including remdesivir in hospitalized adult patients at risk for serious complications. Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.